Evaluating PET scans for predicting treatment response in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational pilot study aims to assess the effectiveness of 18FDG PET-CT scans in predicting the early response to immunotherapy, with or without chemotherapy, in patients diagnosed with locally advanced or metastatic non-small cell lung carcinoma (NSCLC). The study will analyze specific metabolic biomarkers from the PET scans to determine their ability to identify treatment efficacy compared to current standards. Patients enrolled will be those who have been prescribed immunotherapy and meet specific eligibility criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age greater than or equal to 18 years,
* Patients with histologically proven, metastatic or locally advanced NSCLC, with indication for immunotherapy (Nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab), in combination or not with chemotherapy molecules (carboplatin, cisplatin, pemetrexed, paclitaxel or nab-paclitaxel), validated by a Multidisciplinary Team and prescribed within the scope of their Marketed Authorization, whatever the line of treatment treatment line,
* ECOG 0 to 3,
* The patient's understanding of the protocol and the note of non-opposition, with oral agreement,
* Patient has not objected to the use of his or her data for medical research. research,
* Patient has social security coverage.

Exclusion Criteria:

* Age under 18,
* Contraindication to 18FDG PET-CT examinations: severe claustrophobia, unbalanced diabetes at the time of the first PET-CT scan (fasting capillary glucose ≥ 11 mmol),
* Hemoglobin less than 7 g/dL at inclusion. If the patient has a respiratory or or cardiovascular pathology, hemoglobin must not be less than 9.0 g/dL,
* Any participation in other biomedical studies involving the drug, medical devices or medical devices or imaging techniques is prohibited, with the exception of biomedical studies,
* Refusal to participate in the present study,
* Contraindication (e.g. hypersensitivity to the active substance or to one of the excipients of immunotherapy or chemotherapy treatments...).
* Vulnerable persons are defined in article L1121-5 to -8:

  * Pregnant women, parturients and nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons hospitalized without consent under articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of the provisions of article L. 1121-8,
  * and persons admitted to a health or social establishment for purposes other than research purposes,
  * adults who are the subject of a legal protection measure, or who are unable to exercise their non opposition

Where it's running

• Centre Antoine Lacassagne
  Nice, France Recruiting

Study contacts

• Study coordinator: Study Coordinator
• Email: DRCI-Promotion@nice.unicancer.fr
• Phone: 04 92 03 14 76

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Neoadjuvant Cryo-Thermal Ablation with Toripalimab and Chemo for Resectable NSCLC

  This study tests whether using Cryo-Thermal Ablation before chemo-immunotherapy helps people with resectable NSCLC see better outcomes.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan and 8 other locations · NCT07855965

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• PF-08634404 Alone or with chemotherapy in early-stage or locally advanced NSCLC

  This study tests PF-08634404 by itself or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer that may be surgically removable or were candidates for additional therapy after initial treatment.

  Recruiting at 28 sites Phase 2 Pfizer · Huntsville, Alabama and 36 other locations · NCT07489066

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Radiotherapy to the primary lung tumor in metastatic NSCLC

  This trial tests whether adding radiotherapy to the primary lung tumor, alongside standard drug therapy, helps people with metastatic non-small cell lung cancer live longer and feel better.

  Recruiting Phase 3 Trans Tasman Radiation Oncology Group · Blacktown, New South Wales and 5 other locations · NCT07135882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.